je.st
news
Tag: advanced
The UPS Foundation Links Advanced Tracking Technology with Global Humanitarian Relief Efforts
2015-03-26 20:15:15| Trucking - Topix.net
The UPS Foundation , the philanthropic arm of UPS , today announced the launch of the UPS Relief Link program to help improve the lives of displaced refugees around the world through optimized distribution and tracking of critical supplies in crisis-affected areas. UPS Relief Link combines the use of a hand-held scanning tool and durable identification cards to deliver superior efficiency by eliminating paper records in the refugee camps.
Tags: links
advanced
technology
global
California ARB seeking Grantee to administer pilot project for enabling disadvantaged communities to purchase advanced tech vehicles
2015-03-26 10:55:31| Green Car Congress
Tags: advanced
project
purchase
california
Digital POL Module addresses challenge of powering advanced ICs.
2015-03-25 13:31:08| Industrial Newsroom - All News for Today
Outputting 90 A in 50.80 x 9.47 x 19.10 mm vertical and 50.8 x 19.1 x 9.7 mm horizontal through-hole configurations, non-isolated NDM3Z-90 incorporates dynamically programmable digital features. Modules are available with 7.5–14 Vdc input range and 0.6–1.8 Vdc programmable output range. While peaking at 91.4% at 12 Vdc in to 1.0 Vdc out at 50% load, efficiency remains at 88.7% up to full load. Digital power controller with ChargeMode™ Control technology eliminates need for compensation.
Tags: advanced
digital
challenge
addresses
California Energy Commission awards $24.9M to 9 medium- and heavy-duty advanced truck demo projects
2015-03-25 11:55:30| Green Car Congress
Tags: advanced
california
energy
medium
Mercks Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
2015-03-24 13:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Demonstrated Superior Overall Survival and Progression-Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the randomized, pivotal Phase 3 study (KEYNOTE-006) investigating KEYTRUDA (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the studys independent Data Monitoring Committee. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] next »